Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 12/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29908258 | 0.95 | ROCK2 (0.44) | ACACBGRIN1GRIN2BROCK2ROCK1 | |
| SCHEMBL29627888 | 0.92 | GRIN2B (0.42) | ACACBGRIN1GRIN2BROCK2ROCK1 | |
| SCHEMBL29908262 | 0.88 | ROCK2 (0.39) | GRIN1GRIN2BROCK2ROCK1PIK3CA | |
| SCHEMBL29627965 | 0.87 | GRIN2B (0.41) | ACACBGRIN2BROCK2ROCK1PDE10A | |
| Trifluoroacetic Acid SCHEMBL29908226 | 0.85 | ACACB (0.40) | ACACBGRIN1GRIN2BROCK2ROCK1 | |
| SCHEMBL29627884 | 0.85 | ROCK2 (0.51) | ACACBROCK2ROCK1PDE10APIK3CA | |
| SCHEMBL29627719 | 0.84 | ROCK2 (0.53) | GRIN1GRIN2BROCK2ROCK1 | |
| SCHEMBL29640905 | 0.83 | GAA (0.41) | GRIN1GRIN2BROCK2ROCK1PIK3CA | |
| SCHEMBL29627921 | 0.83 | ROCK2 (0.38) | ROCK2ROCK1PDE10A | |
| SCHEMBL29627898 | 0.83 | HAO1 (0.39) | ACACBGRIN1GRIN2BROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281841-A1 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ANGION BIOMEDICA CORP. | 2022-09-08 | — | — | US | disclosed |
| EP-4003340-A2 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | Angion Biomedica Corp. (US) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281841-A1 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ROCK1, ROCK2, CIT | ACACB 1634/4885GRIN1 4062/4885GRIN2B 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.